📰 Botensilimab/balstilimab produced an estimated 3-year OS rate of 48% in heavily pretreated recurrent ovarian cancer in the ovarian cohort of the phase 1b C-800-01 trial. @danafarber.bsky.social #IGCS2026 #gyncsm #oncology

Read more ➡️: www.onclive.com/view/botensi...

📈 The IDMC overseeing an ongoing phase 2 MRD translational study of IMNN-001 in newly diagnosed advanced ovarian cancer has recommended the trial continue without modification. #gyncsm #oncology

More insights ➡️: www.onclive.com/view/idmc-re...

Responses to ADC TUB-040 did not differ by NaPi2b expression level in platinum-resistant ovarian cancer, supporting a biomarker-unrestricted development path, according to Toon Van Gorp, MD, PhD. @ascocancer.bsky.social #ASCO26 #gyncsm #oncology

More insights ➡️: www.onclive.com/view/napista...

WATCH: Lucy Gilbert, MD, MSc, FRCOG, discusses data from the ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. @ascocancer.bsky.social #ASCO26 #gyncsm #oncology

Full video ➡️: www.onclive.com/view/dr-gilb...

📰 @ascocancer.bsky.social published its first living guideline on the treatment of recurrent high-grade serous and/or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer. @jco-asco.bsky.social #gyncsm #oncology

Learn more: www.onclive.com/view/asco-is...